Earlier Access to Effective Treatments for Children with MS Reduces the Burden of Long-Term Disability
New research presented at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood significantly reduces long-term disability in multiple sclerosis patients.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
